These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

927 related items for PubMed ID: 23733925

  • 1. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
    Hillier SM, Maresca KP, Lu G, Merkin RD, Marquis JC, Zimmerman CN, Eckelman WC, Joyal JL, Babich JW.
    J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
    [Abstract] [Full Text] [Related]

  • 2. Novel technetium-99m-labeled bivalent PSMA-targeting probe based on hydroxamamide chelate for diagnosis of prostate cancer.
    Shimizu Y, Ando M, Watanabe H, Ono M.
    Ann Nucl Med; 2024 Oct; 38(10):847-851. PubMed ID: 38976087
    [Abstract] [Full Text] [Related]

  • 3. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
    Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N, Zimmerman CN, Barrett JA, Eckelman WC, Pomper MG, Joyal JL, Babich JW.
    Cancer Res; 2009 Sep 01; 69(17):6932-40. PubMed ID: 19706750
    [Abstract] [Full Text] [Related]

  • 4. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer.
    Vallabhajosula S, Nikolopoulou A, Babich JW, Osborne JR, Tagawa ST, Lipai I, Solnes L, Maresca KP, Armor T, Joyal JL, Crummet R, Stubbs JB, Goldsmith SJ.
    J Nucl Med; 2014 Nov 01; 55(11):1791-8. PubMed ID: 25342385
    [Abstract] [Full Text] [Related]

  • 5. 99mTc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen.
    Xu X, Zhang J, Hu S, He S, Bao X, Ma G, Luo J, Cheng J, Zhang Y.
    Nucl Med Biol; 2017 May 01; 48():69-75. PubMed ID: 28273495
    [Abstract] [Full Text] [Related]

  • 6. Preparation and Biological Evaluation of [99mTc]Tc-CNGU as a PSMA-Targeted Radiotracer for the Imaging of Prostate Cancer.
    Xiao D, Duan X, Gan Q, Zhang X, Zhang J.
    Molecules; 2020 Nov 26; 25(23):. PubMed ID: 33256058
    [Abstract] [Full Text] [Related]

  • 7. Clinical translation of a PSMA inhibitor for 99mTc-based SPECT.
    Ferro-Flores G, Luna-Gutiérrez M, Ocampo-García B, Santos-Cuevas C, Azorín-Vega E, Jiménez-Mancilla N, Orocio-Rodríguez E, Davanzo J, García-Pérez FO.
    Nucl Med Biol; 2017 May 26; 48():36-44. PubMed ID: 28193503
    [Abstract] [Full Text] [Related]

  • 8. Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer.
    Evazalipour M, D'Huyvetter M, Tehrani BS, Abolhassani M, Omidfar K, Abdoli S, Arezumand R, Morovvati H, Lahoutte T, Muyldermans S, Devoogdt N.
    Contrast Media Mol Imaging; 2014 May 26; 9(3):211-20. PubMed ID: 24700748
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. PMPA for nephroprotection in PSMA-targeted radionuclide therapy of prostate cancer.
    Kratochwil C, Giesel FL, Leotta K, Eder M, Hoppe-Tich T, Youssoufian H, Kopka K, Babich JW, Haberkorn U.
    J Nucl Med; 2015 Feb 26; 56(2):293-8. PubMed ID: 25613537
    [Abstract] [Full Text] [Related]

  • 13. Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA).
    Ray Banerjee S, Pullambhatla M, Foss CA, Falk A, Byun Y, Nimmagadda S, Mease RC, Pomper MG.
    J Med Chem; 2013 Aug 08; 56(15):6108-21. PubMed ID: 23799782
    [Abstract] [Full Text] [Related]

  • 14. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA).
    Banerjee SR, Foss CA, Castanares M, Mease RC, Byun Y, Fox JJ, Hilton J, Lupold SE, Kozikowski AP, Pomper MG.
    J Med Chem; 2008 Aug 14; 51(15):4504-17. PubMed ID: 18637669
    [Abstract] [Full Text] [Related]

  • 15. Design, synthesis, radiolabeling and biological evaluation of new urea-based peptides targeting prostate specific membrane antigen.
    Mosayebnia M, Hajimahdi Z, Beiki D, Rezaeianpour M, Hajiramezanali M, Geramifar P, Sabzevari O, Amini M, Hatamabadi D, Shahhosseini S.
    Bioorg Chem; 2020 Jun 14; 99():103743. PubMed ID: 32217372
    [Abstract] [Full Text] [Related]

  • 16. PSMA SPECT/CT with 99mTc-MIP-1404 in biochemical recurrence of prostate cancer: predictive factors and efficacy for the detection of PSMA-positive lesions at low and very-low PSA levels.
    Schmidkonz C, Goetz TI, Kuwert T, Ritt P, Prante O, Bäuerle T, Goebell P, Cordes M.
    Ann Nucl Med; 2019 Dec 14; 33(12):891-898. PubMed ID: 31502084
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Development of 18F-Fluoroglycosylated PSMA-Ligands with Improved Renal Clearance Behavior.
    Potemkin R, Strauch B, Kuwert T, Prante O, Maschauer S.
    Mol Pharm; 2020 Mar 02; 17(3):933-943. PubMed ID: 32011889
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.